Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

Anna Reustle(University of Tübingen), Elke Schaeffeler(German Cancer Research Center)

Genome Medicine

March 30, 2020

10.1186/s13073-020-00731-8

Cited by 102

Related Papers

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

|The Lancet|2023|508

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma

|BMC Medicine|2018|30

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

|Genome Medicine|2022|29